RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

YANTAI, China, Aug. 18, 2025 /PRNewswire/ — RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, “RemeGen”), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. (“Santen China”), a wholly-owned…